title: Carcinogenic risk of bath PUVA in comparison to oral PUVA therapy.
abstract: The potential carcinogenic risk of bath PUVA therapy was compared to that of systemic (oral) PUVA. An analysis of the epidemiological data on cancer risk following bath PUVA with trimethylpsoralen does not support the conclusion that bath PUVA per se is less carcinogenic than systemic PUVA with 8-methoxypsoralen (8-MOP). Pharmacokinetic studies indicate that both the concentration of 8-MOP in the target organ for PUVA carcinogenicity (skin) at the relevant time point (time point of UVA irradiation) and the extents of biological effects in the skin are comparable following bathwater or systemic 8-MOP administration. Furthermore, the therapeutic effects of PUVA arise from the same photochemical reaction mechanisms as do the carcinogenic effects. Theoretically, the ratio of (desired) cytotoxic versus (undesired) mutagenic effects could increase with increasing efficiency of the PUVA therapy itself. On the basis of the available evidence, it is concluded that all forms of PUVA therapy, independently of the route of 8-MOP administration, contribute to a small but dose-dependent increase in nonmelanoma skin cancer risk.
authors.affiliation: Department of Dermatology, University Hospital Zürich, Switzerland. shephard@derm.unizh.ch
authors.forename: S E
authors.initials: SE
authors.lastname: Shephard
authors.forename: R G
authors.initials: RG
authors.lastname: Panizzon
mesh_terms: D000078223:5-Methoxypsoralen; D000284:Administration, Oral; D000287:Administration, Topical; D001494:Baths / Q000009:adverse effects*; D018736:DNA Adducts / Q000096:biosynthesis; D005260:Female; D006801:Humans; D016410:Lymphoma, T-Cell, Cutaneous / Q000188:drug therapy; D008297:Male; D008730:Methoxsalen / Q000008:administration & dosage* / Q000009:adverse effects* / Q000031:analogs & derivatives / Q000493:pharmacokinetics; D016296:Mutagenesis; D011701:PUVA Therapy / Q000009:adverse effects* / Q000379:methods*; D017319:Photosensitizing Agents / Q000008:administration & dosage / Q000009:adverse effects; D011565:Psoriasis / Q000188:drug therapy; D012871:Skin Diseases / Q000188:drug therapy; D012878:Skin Neoplasms / Q000139:chemically induced / Q000453:epidemiology*; D013347:Subcellular Fractions / Q000187:drug effects; D014307:Trioxsalen / Q000008:administration & dosage / Q000009:adverse effects; D014820:Vitiligo / Q000188:drug therapy
chemical_list: D018736:DNA Adducts; D017319:Photosensitizing Agents; D000078223:5-Methoxypsoralen; D008730:Methoxsalen; D014307:Trioxsalen